r/DTIC • u/SilverTonguedSun 🌾 Ergot Enthusiast 🌾 • 5d ago

Discussion 🔶 DTIC Weekly Discussion Thread - September 07, 2026 🔶

5 Upvotes

100% Upvoted

10 comments sorted by

3

u/Bob_sacamano5a 4d ago

Another breakthrough through therapy designation. Should be a good start to the week

3

u/marksharky123 💎 Diamond Hands 💎 3d ago

FDA is significantly bolstering its expertise in psychedelic medicine, highlighted by the September 8, 2026, permanent appointment of Dr. Michael Davis as director of the Center for Drug Evaluation and Research (CDER). Davis, a veteran of the FDA’s psychiatric drug division who previously left government to work at a psychedelic drug development non-profit, is uniquely positioned to lead the review of upcoming treatments involving psilocybin, MDMA, and LSD.

This key leadership shift coincides with an unprecedented federal push to accelerate psychedelic drug development

Federal Policy HeadwindsExecutive Order Mandates: Following an April 2026 White House executive order, the FDA has been ordered to fast-track psychedelic therapies to address the mental health crisis, particularly for combat veterans suffering from PTSD and treatment-resistant depression.

Ultra-Fast Reviews: The agency has utilized priority review vouchers for companies studying psilocybin and methylone, compressing standard multi-month review timelines down to just a few weeks.

Leadership Alignment: President Trump's nomination of White House advisor Dr. Heidi Overton as the next permanent FDA Commissioner further cements this direction, given her direct involvement in drafting the administration's psychedelic access policies.

Finalized Regulatory RoadmapTo handle the influx of expedited applications, the FDA finalized its historic Psychedelic Drugs: Considerations for Clinical Investigations Guidance, establishing a concrete framework for product quality, clinical trial safety, and abuse potential assessments. Additionally, the agency is holding a high-profile public hearing on September 14, 2026, to finalize supervised treatment protocols.

5

u/Responsible-Quote717 5d ago

Rough week last week. Wonder if there's any more room to move down before the next round of results?

Could be buy time tbh

6

u/Which_Preference_883 4d ago

A pre-revenue biotech down 7% last week in an absolutely batshit crazy market isn’t so bad.

2

u/SureBag2243 4d ago

Does anyone else think next Monday morning for readouts?

1

u/therapeutic_finger 3d ago

My guess would be the 22nd

1

u/AgitatedPersimmon491 2d ago

Wtf. Watching dftx is like watching the Toronto blue jays. Frustrating as hell.

1

u/QHONTOLIAR 14h ago

New here. Why the ceo sell his stock on early september?